Blues' TEC Delivers Negative Assessment On Carotid Stenting
This article was originally published in The Gray Sheet
Executive Summary
A recent negative BlueCross BlueShield Association technology assessment could be another barrier to expanded coverage of carotid stenting
You may also be interested in...
Medicare Panel Looks To Upcoming Study To Fill Evidence Gaps For Carotid Artery Disease
There's a lot more to learn about which treatment to choose for carotid atherosclerosis patients, Medicare advisors said this week. A new trial in the works that would compare both surgery and stenting to standalone medical therapy presents a good opportunity to fill the gaps.
Medicare Panel Looks To Upcoming Study To Fill Evidence Gaps For Carotid Artery Disease
There's a lot more to learn about which treatment to choose for carotid atherosclerosis patients, Medicare advisors said this week. A new trial in the works that would compare both surgery and stenting to standalone medical therapy presents a good opportunity to fill the gaps.
FDA Panel Leans In Favor Of Expanded Indication For Abbott’s Carotid Stent
An FDA advisory panel provided support for Abbott's bid to expand labeling for its RX Acculink carotid stent system to treat a larger patient population, despite reservations from some members about safety.